TAVR

SAVR

Inception

2011 (in the U.S.)

1960

Eligible Population (STS-PROM Score)

High risk (>8%), intermediate risk (4% - 8%), low risk (<4%)

Intermediate risk (4% - 8%), low risk (<4%), younger patients

*1/3 of patients not eligible

Procedure

Minimally invasive procedure

Requires full sternotomy or less invasive mini-sternotomy, cardiopulmonary bypass, cross-clamping of the aorta

Bioprosthetic valve is placed directly over the damaged native valve

Native stenotic valve is removed

Small vascular punctures (transfemoral)

Large surgical incision

Conscious sedation with local anesthesia (transfemoral)

General anesthesia with intubation

Procedural Setting

Cardiac catheterization lab

Operating room

Average Procedure Duration

84 mins

236 mins

Average Length of Stay

4.6 days

10.9 days

Valve Cost

$32,000

$5,000

Average Total Admission Costs (including procedure)

$54,256

$58,410

Average 1-Year Cumulative Costs

$80,977

$96,489

2-Year Mortality

13.1%

17.1%